Abbott Laboratories · ABT · Next earnings

Abbott Laboratories reports Thursday, Jan 28, 2027

ABT reports before market open with consensus EPS at $1.64 and revenue at $13.22B. Last quarter: Abbott plans nutrition spin-off as Q3 growth holds, guidance falls

Reports Before market open84 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $1.64 Calendar consensus
Consensus revenue $13.22B Calendar consensus
Report date Jan 28, 2027 Thursday, date estimated
Session Before market open 84 days away

Where ABT left off: FY2026 Q3

Full report

Abbott plans nutrition spin-off as Q3 growth holds, guidance falls

EPS surprise 0.0% Reported $1.42 vs $1.42
Revenue surprise +0.2% Reported $13.01B vs $12.99B
Stock move -1.9% Event window
Subsequent drift 0.0% Up to 20 sessions

Full-year revenue guidance was lowered to roughly 6% growth, reflecting short-term electrophysiology and diabetes headwinds. Management expects post-separation sales growth to accelerate by 50–100 basis points, with more than 200 basis points of gross-margin expansion and about 100 basis points of operating-margin expansion.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Nutrition separation execution and potential NEC litigation liability.
  • Pricing and reimbursement uncertainty for CGM and Cologuard Plus.
  • Electrophysiology product transitions, LAA market dynamics, and a temporary cybersecurity-related diagnostic sales impact.

Questions analysts left open

  • The rationale and timing of the nutrition spin-off, including potential NEC litigation liability.
  • The drivers behind lower FY2026 revenue guidance and the outlook for 2027 EPS growth.
  • CGM and Cologuard Plus pricing, reimbursement, and adoption; electrophysiology headwinds during product transitions.

Ask FN2 about ABT next report

Transcript, numbers and history already loaded
What should I watch for in ABT's next earnings report?How did ABT guide last quarter, and is consensus above or below that?Give me the bull and bear case going into ABT earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the ABT recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent ABT quarters

All ABT earnings
-1.9%FY2026 Q3+10.7%FY2026 Q2-6.0%FY2026 Q1-10.0%FY2025 Q4

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.